Get the Stockscreener App
1.59
2.58%
0.04
Regulus Therapeutics Inc stock is traded at $1.59, with a volume of 441.41K.
It is up +2.58% in the last 24 hours and up +13.57% over the past month.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
See More
Previous Close:
$1.55
Open:
$1.53
24h Volume:
441.41K
Relative Volume:
1.23
Market Cap:
$104.15M
Revenue:
-
Net Income/Loss:
$-30.04M
P/E Ratio:
-0.9408
EPS:
-1.69
Net Cash Flow:
$-27.38M
1W Performance:
+0.63%
1M Performance:
+13.57%
6M Performance:
-36.90%
1Y Performance:
+20.45%
1-Day Range:
$1.5101
$1.60
1-Week Range:
$1.50
$1.70
52-Week Range:
$1.08
$3.79
Regulus Therapeutics Inc Stock (RGLS) Company Profile
Name
Regulus Therapeutics Inc
Sector
Industry
Phone
858-202-6300
Address
4224 CAMPUS POINT COURT, SAN DIEGO, CA
Compare RGLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGLS
Regulus Therapeutics Inc
|
1.59 | 104.15M | 0 | -30.04M | -27.38M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-02-24 | Initiated | Oppenheimer | Outperform |
| Mar-18-24 | Initiated | Leerink Partners | Outperform |
| Mar-28-18 | Initiated | B. Riley FBR, Inc. | Neutral |
| Jan-05-18 | Initiated | Leerink Partners | Outperform |
| Jun-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Mar-06-17 | Reiterated | Wedbush | Outperform |
| Jan-30-17 | Downgrade | Needham | Buy → Hold |
| Jan-30-17 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Dec-07-16 | Reiterated | Chardan Capital Markets | Buy |
| Nov-02-16 | Reiterated | Needham | Buy |
| Jul-25-16 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | FBR Capital | Outperform |
| Jun-28-16 | Reiterated | Needham | Buy |
| Jun-07-16 | Reiterated | Chardan Capital Markets | Buy |
| Apr-13-16 | Initiated | Chardan Capital Markets | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Jun-09-15 | Initiated | Guggenheim | Buy |
| Apr-21-15 | Resumed | FBR Capital | Outperform |
| Nov-24-14 | Initiated | Deutsche Bank | Buy |
| Aug-07-14 | Reiterated | FBR Capital | Outperform |
| Aug-14-13 | Reiterated | Needham | Buy |
View All
Regulus Therapeutics Inc Stock (RGLS) Latest News
Institutional investors may overlook Regulus Therapeutics Inc.'s (NASDAQ:RGLS) recent US$12m market cap drop as long-term gains remain positive - Simply Wall St
Fmr LLC Has $515,000 Stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat
Regulus To Provide First Quarter 2017 Financial Results On May 4, 2017 - BioSpace
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average Price Target from Brokerages - MarketBeat
The Manufacturers Life Insurance Company Purchases New Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - StockTitan
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences - Longview News-Journal
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences - The Eastern Progress Online
Point72 Asset Management L.P. Takes $1.40 Million Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat
With 64% institutional ownership, Regulus Therapeutics Inc. (NASDAQ:RGLS) is a favorite amongst the big guns - Yahoo Finance
RA Capital Management L.P. Sells 5,483,166 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat
NEA Management Company LLC Buys Shares of 6,467,802 Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat
Victory Capital Management Inc. Has $626,000 Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics Announces Participation at Upcoming Healthc - GuruFocus.com
Regulus Therapeutics to Present at Evercore and Piper Sandler Healthcare Conferences - StockTitan
Brokerages Set Regulus Therapeutics Inc. (NASDAQ:RGLS) Price Target at $10.80 - MarketBeat
Regulus Therapeutics Reports Q3 2024 Financial Results - TipRanks
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates - GuruFocus.com
Annovis Bio (NYSE:ANVS) versus Regulus Therapeutics (NASDAQ:RGLS) Head-To-Head Contrast - Defense World
RA Capital Management's Strategic Reduction in Regulus Therapeutics Holdings - GuruFocus.com
Biotechnology Value Fund L.P. Increases Stake in Regulus Therape - GuruFocus.com
What is HC Wainwright’s Estimate for RGLS FY2024 Earnings? - Defense World
FY2024 Earnings Forecast for RGLS Issued By HC Wainwright - MarketBeat
Creative Planning Makes New Investment in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Receives Buy Rating from HC Wainwright - MarketBeat
Regulus: Q3 Earnings Snapshot - San Francisco Chronicle
Regulus Therapeutics (RGLS) Stock Price, News & Analysis - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Regulus Therapeuti - GuruFocus.com
HC Wainwright Reiterates Buy Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average PT from Analysts - MarketBeat
These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts - Yahoo Finance
Regulus Therapeutics secures exclusive license for kidney disease treatment - Investing.com India
Regulus Therapeutics secures exclusive license for kidney disease treatment By Investing.com - Investing.com South Africa
Regulus Therapeutics Inc. Enters into Patent & Technology License Agreement with the Board of Regents of the University of Texas System - Marketscreener.com
Financial Survey: Regulus Therapeutics (NASDAQ:RGLS) & Ironwood Pharmaceuticals (NASDAQ:IRWD) - Defense World
Renaissance Technologies LLC Has $211,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
HC Wainwright Reaffirms "Buy" Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat
RGLSRegulus Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PR Newswire
Analysts Set Regulus Therapeutics Inc. (NASDAQ:RGLS) PT at $10.80 - MarketBeat
Company’s Banking Stock: Dissecting a -7.22% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Regulus Therapeutics Inc [RGLS] stock for 7,280 USD was acquired by Collier Kathryn J - Knox Daily
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Sold by CVI Holdings LLC - MarketBeat
Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth - Simply Wall St
ProMIS Neurosciences (NASDAQ:PMN) versus Regulus Therapeutics (NASDAQ:RGLS) Critical Contrast - Defense World
Investing in Regulus Therapeutics Inc (RGLS) Is Getting More Attractive - Knox Daily
Victory Capital Management Inc. Has $645,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Stock Rating Upgraded by StockNews.com - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Upgraded to "Sell" by StockNews.com - MarketBeat
Oppenheimer’s latest rating for RGLS stock - Knox Daily
RGLS stock rated an Outperform by Oppenheimer - Knox Daily
Regulus Therapeutics Inc Stock (RGLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):